VRT106 drug combined with radiation for brain stem tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether a new drug called VRT106, given alongside radiation therapy, can help treat a serious type of brain tumor called diffuse midline glioma or DIPG. The drug is designed to work with radiation to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- You have a confirmed diagnosis of H3 K27-altered diffuse midline glioma or DIPG (based on biopsy or MRI showing a tumor in the pons taking up more than half of it)
- Your overall health and ability to care for yourself is reasonably good (Karnofsky score of 60 or higher)
- Your doctor believes you will likely live at least 3 more months
- You have no cancer spread outside the brain or spinal cord tumors
- You can safely have MRI scans (no incompatible implants like certain pacemakers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
This trial tests a new way of giving radiation therapy for a type of brain tumor called diffuse midline glioma. It aims to see if splitting the radiation into smaller courses can help while reducing side effects.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This trial tests a new drug called VRT106 combined with chemotherapy for people with pancreatic cancer that can be surgically removed. The goal is to see if the combination works better than standard treatment alone.
This trial tests a new injection called VRT106 for people whose glioblastoma (a brain tumor) has come back or is growing. It uses a virus that may help the immune system attack the tumor. This study is for those who have not had a similar virus or gene therapy before.
Hear when a new Diffuse Midline Glioma, H3 K27M-Mutant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.